Alaunos Therapeutics (NASDAQ:TCRT) Announces Earnings Results

Posted by Stanley Muller on Aug 15th, 2026

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.41) earnings per share (EPS) for the quarter, FiscalAI reports.

Alaunos Therapeutics Stock Performance

TCRT traded down $0.06 during trading on Friday, reaching $1.93. 11,146 shares of the company’s stock were exchanged, compared to its average volume of 9,252. The company’s fifty day moving average price is $2.06 and its 200-day moving average price is $2.56. Alaunos Therapeutics has a fifty-two week low of $1.67 and a fifty-two week high of $4.59. The firm has a market capitalization of $47.13 million, a PE ratio of -0.91 and a beta of -1.00.

Institutional Investors Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. HRT Financial LP purchased a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned 0.54% of Alaunos Therapeutics at the end of the most recent reporting period. 27.72% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Alaunos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Check Out Our Latest Analysis on Alaunos Therapeutics

Alaunos Therapeutics Company Profile

(Get Free Report)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.